別品名 |
Ruxolitinib
|
別包装 |
あり
|
純度 |
>=98%
|
分子量 |
306.37
|
CAS RN® |
941678-49-5
|
化合物の概要 |
JAK1/2 inhibitor.
|
構造 |
C17H18N6
|
溶媒 |
DMSO61 mg/mL (199.1 mM)Ethanol61 mg/mL (199.1 mM)WaterInsoluble
|
使用目的 |
INCB018424 is an inhibitor of JAK1/2 that is clinically used to treat rheumatoid arthritis and myelofibrosis. INCB018424 exhibits anticancer, anti-inflammatory, and antiviral activities. In myeloma cells, INCB018424 inhibits cell growth. INCB018424 also inhibits in vitro infection by HIV-1, HIV-2, and SHIV by preventing viral replication in lymphocytes. In animal models of CCL4-induced hepatic injury, INCB018424 prevents inflammation by decreasing neutrophil and macrophage infiltration, suppressing activation of NF-κB, and limiting release of TNF-α, IL-10, and IL-1β.
|
その他 |
[外観]Yellow to off white powder
|
参考文献 |
Springuel L, Hornakova T, Losdyck E, et al. Cooperating JAK1 and JAK3 mutants increase resistance to JAK inhibitors. Blood. 2014 Dec 18;124(26):3924-31. PMID: 25352124.Hazem SH, Shaker ME, Ashamallah SA, et al. The novel Janus kinase inhibitor ruxolitinib confers protection against carbon tetrachloride-induced hepatotoxicity via multiple mechanisms. Chem Biol Interact. 2014 Sep 5;220:116-27. PMID: 24973641.Gavegnano C, Detorio M, Montero C, et al. Ruxolitinib and tofacitinib are potent and selective inhibitors of HIV-1 replication and virus reactivation in vitro. Antimicrob Agents Chemother. 2014;58(4):1977-86. PMID: 24419350.
|
|
メーカー |
品番 |
包装 |
LKT
|
I5210
|
50 MG
|
※表示価格について
当社在庫 |
なし
|
納期目安 |
1週間程度
|
法規制 |
劇
|
保存温度 |
-20℃
|
|